首页> 外文期刊>Cancer Biomarkers >Evaluation of protein expression pattern of stanniocalcin 2, insulin-like growth factor-binding protein 7, inhibin beta A and four and a half LIM domains 1 in esophageal squamous cell carcinoma
【24h】

Evaluation of protein expression pattern of stanniocalcin 2, insulin-like growth factor-binding protein 7, inhibin beta A and four and a half LIM domains 1 in esophageal squamous cell carcinoma

机译:食管鳞癌中斯坦钙蛋白2,胰岛素样生长因子结合蛋白7,抑制素βA和四个半LIM结构域1蛋白表达谱的评价

获取原文
获取原文并翻译 | 示例
           

摘要

The pathogenesis of esophageal squamous cell carcinoma (ESCC) involves both genetic and environmental factors. Previously, we have carried out gene and protein expression profiling of ESCC using DNA microarrays and mass spectrometry-based quantitative proteomics, respectively. These studies resulted in identification of several potential biomarkers of ESCC, some with known reports of differential expression in the scientific literature and others that were novel observations from our studies. We report systematic validation of selected markers from our studies on a larger cohort of cancer tissue sections by immunohistochemical labeling of tissue microarrays. We have validated expression of insulin-like growth factor-binding protein 7 (IGFBP7), stanniocalcin 2 (STC2), inhibin beta A (INHBA) and four and a half LIM domains 1 (FHL1). Immunohistochemical labeling with anti-stanniocalcin 2 antibody demonstrated its overexpression in 132/140 (94%) cases, IGFBP7 showed overexpression in 127/140 (91%) cases and overexpression of INHBA was observed in 62/105 (59%) of ESCC cases. In contrast, FHL1 expression was observed only in 12/143 (8%) of ESCC cases suggesting its possible involvement in tumor suppression. These data suggest that IGFBP7, INHBA, STC2 and FHL1 might play an important role in ESCC tumorigenesis, which can be explored in future studies. Overall, our findings open up new avenues for development of novel therapeutics and/or diagnostic approaches in ESCC.
机译:食管鳞状细胞癌(ESCC)的发病机制涉及遗传和环境因素。以前,我们分别使用DNA微阵列和基于质谱的定量蛋白质组学进行了ESCC的基因和蛋白质表达谱分析。这些研究导致鉴定出几种潜在的ESCC生物标志物,其中一些在科学文献中有差异表达的已知报道,而另一些则是我们研究中的新颖观察结果。我们报告了通过组织微阵列的免疫组织化学标记,从我们对较大癌症组织切片的研究中所选标记的系统验证。我们已经验证了胰岛素样生长因子结合蛋白7(IGFBP7),锡钙素2(STC2),抑制素βA(INHBA)和四个半LIM域1(FHL1)的表达。用抗stanniocalcin 2抗体进行的免疫组织化学标记显示其在132/140(94%)例中过表达,IGFBP7在127/140(91%)的例中过表达,在62/105(59%)的ESCC例中观察到INHBA的过表达。相反,仅在12/143(8%)的ESCC病例中观察到FHL1表达,表明其可能参与了肿瘤抑制。这些数据表明IGFBP7,INHBA,STC2和FHL1可能在ESCC肿瘤发生中起重要作用,这可以在以后的研究中加以探讨。总体而言,我们的发现为ESCC开发新的治疗方法和/或诊断方法开辟了新途径。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号